Head-to-head evidence
Carfilzomib vs Ixazomib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Carfilzomib
Marketed by Amgen and partners
NCT01080391 · Phase 3 · completed
The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).
Next expected readout: October 2026 · NCT06140966 (registry estimate)
Ixazomib
Marketed by Takeda Pharmaceutical Company and partners
NCT01564537 · Phase 3 · completed
Participants were randomly assigned and quadruple-blinded to ixazomib plus lenalidomide and dexamethasone or matching placebo plus lenalidomide and dexamethasone, with 360 and 362 participants, respectively. The hard clinical primary endpoint of independently assessed progression-free survival was met: median progression-free survival was 20.6 versus 14.7 months, with a statistically significant difference between groups (p=0.012).
Next expected readout: March 2027 · NCT04068597 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carfilzomib's landscape · Ixazomib's landscape